Evaluation of the safety of C-1311 (SYMADEX) administered in a phase 1 dose escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumours
Nicolás Isambert(Centre Georges François Leclerc), P. Fumoleau(Institut Curie), Charles K. Grieshaber, A. Major, Mario Campone(Institut de Cancérologie de l'Ouest), Emmanuelle Bourbouloux(Centre Hospitalier René-Dubos), Wenxuan Yin(Tongji University), Robert L. Capizzi, M. Drouin(Western University), Paul M. Loadman(University of Bradford)
Cited by 45
Related Papers
Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment
|Journal of Clinical Oncology|2007|483
Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer
|Journal of Clinical Oncology|2007|290
Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine
|Journal of Clinical Oncology|2010|217